Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer

International Journal of Cancer

Volumn 122, Issue 11, 2008, Pages 2646-

  Patani, Neill ^a   Jiang, Wen ^b   Mokbel, Kefah ^a,c,d  

^a Princess Grace Hospital   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d Princess Grace Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; OSTEOPONTIN; OSTEOPONTIN C;

BREAST CANCER; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 42549101808     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23402     Document Type: Letter

References (1)

1. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008;122:889-97.